Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. / Relling, M V; Gardner, E E; Sandborn, W J; Schmiegelow, K; Pui, C-H; Yee, S W; Stein, Paul C.; Carrillo, Maria Berrocal; Evans, W E; Klein, T E; Clinical Pharmacogenetics Implementation Consortium.

I: Clinical Pharmacology and Therapeutics, Bind 89, Nr. 3, 2011, s. 387-91.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Relling, MV, Gardner, EE, Sandborn, WJ, Schmiegelow, K, Pui, C-H, Yee, SW, Stein, PC, Carrillo, MB, Evans, WE, Klein, TE & Clinical Pharmacogenetics Implementation Consortium 2011, 'Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing', Clinical Pharmacology and Therapeutics, bind 89, nr. 3, s. 387-91. https://doi.org/10.1038/clpt.2010.320

APA

Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C-H., Yee, S. W., Stein, P. C., Carrillo, M. B., Evans, W. E., Klein, T. E., & Clinical Pharmacogenetics Implementation Consortium (2011). Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clinical Pharmacology and Therapeutics, 89(3), 387-91. https://doi.org/10.1038/clpt.2010.320

Vancouver

Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui C-H, Yee SW o.a. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clinical Pharmacology and Therapeutics. 2011;89(3):387-91. https://doi.org/10.1038/clpt.2010.320

Author

Relling, M V ; Gardner, E E ; Sandborn, W J ; Schmiegelow, K ; Pui, C-H ; Yee, S W ; Stein, Paul C. ; Carrillo, Maria Berrocal ; Evans, W E ; Klein, T E ; Clinical Pharmacogenetics Implementation Consortium. / Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. I: Clinical Pharmacology and Therapeutics. 2011 ; Bind 89, Nr. 3. s. 387-91.

Bibtex

@article{2c9007ae212e4322a5479ba0fe48d34b,

title = "Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing",

abstract = "Thiopurine methyltransferase (TPMT) activity exhibits monogenic co-dominant inheritance, with ethnic differences in the frequency of occurrence of variant alleles. With conventional thiopurine doses, homozygous TPMT-deficient patients (~1 in 178 to 1 in 3,736 individuals with two nonfunctional TPMT alleles) experience severe myelosuppression, 30-60% of individuals who are heterozygotes (~3-14% of the population) show moderate toxicity, and homozygous wild-type individuals (~86-97% of the population) show lower active thioguanine nucleolides and less myelosuppression. We provide dosing recommendations (updates at http://www.pharmgkb.org) for azathioprine, mercaptopurine (MP), and thioguanine based on TPMT genotype.",

author = "Relling, {M V} and Gardner, {E E} and Sandborn, {W J} and K Schmiegelow and C-H Pui and Yee, {S W} and Stein, {Paul C.} and Carrillo, {Maria Berrocal} and Evans, {W E} and Klein, {T E} and K. Schmiegelow",

year = "2011",

doi = "http://dx.doi.org/10.1038/clpt.2010.320",

language = "English",

volume = "89",

pages = "387--91",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "JohnWiley & Sons, Inc.",

number = "3",

}

RIS

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing

AU - Relling, M V

AU - Gardner, E E

AU - Sandborn, W J

AU - Schmiegelow, K

AU - Pui, C-H

AU - Yee, S W

AU - Stein, Paul C.

AU - Carrillo, Maria Berrocal

AU - Evans, W E

AU - Klein, T E

AU - Clinical Pharmacogenetics Implementation Consortium

PY - 2011

Y1 - 2011

N2 - Thiopurine methyltransferase (TPMT) activity exhibits monogenic co-dominant inheritance, with ethnic differences in the frequency of occurrence of variant alleles. With conventional thiopurine doses, homozygous TPMT-deficient patients (~1 in 178 to 1 in 3,736 individuals with two nonfunctional TPMT alleles) experience severe myelosuppression, 30-60% of individuals who are heterozygotes (~3-14% of the population) show moderate toxicity, and homozygous wild-type individuals (~86-97% of the population) show lower active thioguanine nucleolides and less myelosuppression. We provide dosing recommendations (updates at http://www.pharmgkb.org) for azathioprine, mercaptopurine (MP), and thioguanine based on TPMT genotype.

AB - Thiopurine methyltransferase (TPMT) activity exhibits monogenic co-dominant inheritance, with ethnic differences in the frequency of occurrence of variant alleles. With conventional thiopurine doses, homozygous TPMT-deficient patients (~1 in 178 to 1 in 3,736 individuals with two nonfunctional TPMT alleles) experience severe myelosuppression, 30-60% of individuals who are heterozygotes (~3-14% of the population) show moderate toxicity, and homozygous wild-type individuals (~86-97% of the population) show lower active thioguanine nucleolides and less myelosuppression. We provide dosing recommendations (updates at http://www.pharmgkb.org) for azathioprine, mercaptopurine (MP), and thioguanine based on TPMT genotype.

U2 - http://dx.doi.org/10.1038/clpt.2010.320

DO - http://dx.doi.org/10.1038/clpt.2010.320

M3 - Journal article

VL - 89

SP - 387

EP - 391

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -

ID: 40193073